Cargando…
A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy
In recent years, immunotherapy has become a hot spot in the treatment of tumors. As an emerging treatment, it solves many problems in traditional cancer treatment and has now become the main method for cancer treatment. Although immunotherapy is promising, most patients do not respond to treatment o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818678/ https://www.ncbi.nlm.nih.gov/pubmed/35140720 http://dx.doi.org/10.3389/fimmu.2022.809761 |
_version_ | 1784645878455205888 |
---|---|
author | Liu, Zaoqu Ren, Yuqing Weng, Siyuan Xu, Hui Li, Lifeng Han, Xinwei |
author_facet | Liu, Zaoqu Ren, Yuqing Weng, Siyuan Xu, Hui Li, Lifeng Han, Xinwei |
author_sort | Liu, Zaoqu |
collection | PubMed |
description | In recent years, immunotherapy has become a hot spot in the treatment of tumors. As an emerging treatment, it solves many problems in traditional cancer treatment and has now become the main method for cancer treatment. Although immunotherapy is promising, most patients do not respond to treatment or develop resistance. Therefore, in order to achieve a better therapeutic effect, combination therapy has emerged. The combination of immune checkpoint inhibition and epigenetic therapy is one such strategy. In this review, we summarize the current understanding of the key mechanisms of how epigenetic mechanisms affect cancer immune responses and reveal the key role of epigenetic processes in regulating immune cell function and mediating anti-tumor immunity. In addition, we highlight the outlook of combined epigenetic and immune regimens, particularly the combination of immune checkpoint blockade with epigenetic agents, to address the limitations of immunotherapy alone. |
format | Online Article Text |
id | pubmed-8818678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88186782022-02-08 A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy Liu, Zaoqu Ren, Yuqing Weng, Siyuan Xu, Hui Li, Lifeng Han, Xinwei Front Immunol Immunology In recent years, immunotherapy has become a hot spot in the treatment of tumors. As an emerging treatment, it solves many problems in traditional cancer treatment and has now become the main method for cancer treatment. Although immunotherapy is promising, most patients do not respond to treatment or develop resistance. Therefore, in order to achieve a better therapeutic effect, combination therapy has emerged. The combination of immune checkpoint inhibition and epigenetic therapy is one such strategy. In this review, we summarize the current understanding of the key mechanisms of how epigenetic mechanisms affect cancer immune responses and reveal the key role of epigenetic processes in regulating immune cell function and mediating anti-tumor immunity. In addition, we highlight the outlook of combined epigenetic and immune regimens, particularly the combination of immune checkpoint blockade with epigenetic agents, to address the limitations of immunotherapy alone. Frontiers Media S.A. 2022-01-24 /pmc/articles/PMC8818678/ /pubmed/35140720 http://dx.doi.org/10.3389/fimmu.2022.809761 Text en Copyright © 2022 Liu, Ren, Weng, Xu, Li and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Liu, Zaoqu Ren, Yuqing Weng, Siyuan Xu, Hui Li, Lifeng Han, Xinwei A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy |
title | A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy |
title_full | A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy |
title_fullStr | A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy |
title_full_unstemmed | A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy |
title_short | A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy |
title_sort | new trend in cancer treatment: the combination of epigenetics and immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818678/ https://www.ncbi.nlm.nih.gov/pubmed/35140720 http://dx.doi.org/10.3389/fimmu.2022.809761 |
work_keys_str_mv | AT liuzaoqu anewtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT renyuqing anewtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT wengsiyuan anewtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT xuhui anewtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT lilifeng anewtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT hanxinwei anewtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT liuzaoqu newtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT renyuqing newtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT wengsiyuan newtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT xuhui newtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT lilifeng newtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy AT hanxinwei newtrendincancertreatmentthecombinationofepigeneticsandimmunotherapy |